Ridgefield: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (USFDA) has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults.

SPEVIGO is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP.

"GPP flares can greatly impact a patient's life and lead to serious, life-threatening complications," said Mark Lebwohl, M.D., lead investigator and publication author, and Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, Kimberly and Eric J.

Waldman Department of Dermatology, New York. "The approval of SPEVIGO is a turning point for dermatologists and clinicians."

Click for more on USFDA

"We now have an USFDA-approved treatment that may help make a difference for our patients who, until now, have not had any approved options to help manage GPP flares."

Distinct from plaque psoriasis, GPP is a rare and potentially life-threatening neutrophilic skin disease that is characterized by flares (episodes of widespread eruptions of painful, sterile pustules).

In the United States, it is estimated that 1 out of every 10,000 people has GPP. Given that it is so rare, recognizing the signs and symptoms can be challenging and consequently lead to delays in diagnosis.

"This important approval reflects our successful efforts to accelerate our research with the aim to bring innovative treatments faster to the people most in need," said Carinne Brouillon, Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim.

"We recognize how devastating this rare skin disease can be for patients, their families, and caregivers. GPP can be life-threatening and until today there have been no specific approved therapies for treating the devastating GPP flares."

"It makes me proud that with the approval of SPEVIGO we can now offer the first U.S. approved treatment option for those in need."

In the 12-week pivotal Effisayil 1 clinical trial, patients experiencing a GPP flare (N = 53) were treated with SPEVIGO or placebo. After one week, patients treated with SPEVIGO showed no visible pustules (54% compared to placebo (6%).

"GPP can have an enormous impact on a patient's physical and emotional wellbeing."

"With the USFDA approval of this new treatment, people living with GPP now have hope in knowing that there is an option to help treat their flares," said Thomas Seck, M.D., Senior Vice President, Medicine, and Regulatory Affairs, Boehringer Ingelheim.

"SPEVIGO represents Boehringer Ingelheim's commitment to delivering meaningful change for patients living with serious diseases with limited treatment options."

Other drugs approval by USFDA

USFDA gives approval to Loperamide HCL and Simethicone Tablets

USFDA gives final approval for Chlorthalidone Tablets USP

USFDA gives tentative nod for Dasatinib tablets

USFDA gives approval for this Contraceptive

USFDA gives nod for Formoterol Fumarate inhalation solution

USFDA gives nod for generic Carbamazepine tablets

Safe blood transfusion is still a challenge for thalassemia patients

Drug recall: Zydus, Lupin recall products due to this issue

Pharmacy Council: Elections process to elect 6 members begins

Bulk drug park: Booster shot for Pharma companies

NPPA seeks pricing details of Sodium Chloride 0.45% injection

USFDA issues Form 483 with 11 observation to Biocon

QR code on APIs – Active Pharmaceutical Ingredients

USFDA issues Form 483 with 2 observation to Alembic

NPPA: Silver jubilee celebrations of NPPA 

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/09/06/usfda-gives-nod-for-spevigo-to-treat-generalized-pustular-psoriasis-flares/